Immune Biosolutions inc.
$74,900.00 CAD
≈ 12 months of average Canadian pay
- Department
- National Research Council Canada
- Recipient country
- Canada
- Fiscal year
- 2024-2025
- Agreement period
- November 18, 2024 – March 31, 2025
- Reference
- nrc-cnrc:172-2024-2025-Q3-1024406
Published purpose
The project aims to characterize and evaluate the therapeutic efficacy of bispecific antibodies targeting checkpoint inhibitors of the LILRB family as monotherapy.
Community tags
Tags are applied by readers, not by this site. One tag per person per record.
Good value
Local impact
Needs context
Questionable
Success story
Wasteful
View official source record
Imported July 30, 2026 from open.canada.ca Grants & Contributions